Amphastar Pharmaceuticals, Inc.

As of October 31, 2025, Amphastar Pharmaceuticals shows a mildly bullish trend despite significant underperformance against the S&P 500, with mixed signals from technical indicators suggesting caution.

As of October 31, 2025, Amphastar Pharmaceuticals, Inc. shows a mildly bullish trend based on daily moving averages, despite bearish signals from weekly and monthly indicators, and has underperformed the S&P 500 with a return of -49.53% compared to its 19.89%.

As of October 31, 2025, Amphastar Pharmaceuticals shows a mildly bullish technical trend despite significant underperformance against the S&P 500, with year-to-date and one-year returns of -31.32% and -49.53%, respectively.

As of August 7, 2025, Amphastar Pharmaceuticals, Inc. has shifted to a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, and the stock has significantly underperformed the S&P 500 with a year-to-date return of -26.10%.

As of July 7, 2025, Amphastar Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 10 and an attractive valuation grade, despite a year-to-date return of -26.10% and a 1-year return of -44.88%, indicating a disconnect between its valuation metrics and market sentiment.

As of May 7, 2025, Amphastar Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 10, significantly lower than peers like Corcept Therapeutics at 60.68, and despite a year-to-date return of -33.53%, it is rated as attractive in valuation.

As of May 15, 2025, Amphastar Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals across various time frames, including bearish daily moving averages and a mildly bullish weekly MACD, leading to overall uncertainty in market sentiment.

As of March 2022, the management team of Amphastar Pharmaceuticals, Inc. includes Dr. Mary Luo (COO and Chairman), Mr. Jack Zhang (CEO), and several independent directors, including Mr. Richard Prins and Ms. Diane Gerst, overseeing the company's operations and strategy.

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and sells generic and injectable products. As of March 2025, it reported net sales of $171 million and a net profit of $25 million, with a market cap of approximately $1.41 billion.

As of Jun 18, Amphastar Pharmaceuticals, Inc. has a market capitalization of $1.41 billion, with net sales of $730.65 million and a net profit of $141.63 million over the latest four quarters. The balance sheet shows shareholder's funds of $732.30 million and total assets of $1.62 billion.